AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22813645 — intervention group
Group type: COMPARATOR
Intervention: Delayed therapy with HIV primary care but ART initiated later
Number of subjects: 1763
Study 21140357 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte‐depleting filter
Number of subjects: 52
Study 21140357 — intervention group
Group type: COMPARATOR
Intervention: Control group (without leukocyte‐depleting filter)
Number of subjects: 52
Study 17997834 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-tailored intervention (FATaintPHAT)
Number of subjects: 20
Study 15501923 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term head-down-tilt bed rest (HDT) for 120 days
Number of subjects: 6
Study 11896120 — intervention group
Group type: EXPERIMENTAL
Intervention: CVI 5‐FU (300 mg/m² CVI for 7 days)
Number of subjects: 33
Study 11896120 — intervention group
Group type: COMPARATOR
Intervention: Oral eniluracil/5‐FU (10:1 mg/m² BID for 7 days)
Number of subjects: 33
Study 11896120 — intervention group
Group type: EXPERIMENTAL
Intervention: Eniluracil/5‐FU (BID for 28 days)
Number of subjects: 33
Study 11905937 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% CHO solution
Number of subjects: 7
Study 11905937 — intervention group
Group type: COMPARATOR
Intervention: Non-caloric placebo
Number of subjects: 7
Study 9892912 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 55
Study 9892912 — intervention group
Group type: COMPARATOR
Intervention: Terbinafine
Number of subjects: 55
Study 8116715 — intervention group
Group type: EXPERIMENTAL
Intervention: Korotkoff phase IV
Number of subjects: 1194
Study 8116715 — intervention group
Group type: EXPERIMENTAL
Intervention: Korotkoff phase V
Number of subjects: 1194
Study 3421205 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental diets measured by food weighing and bomb calorimetry for 56 or 42 days.
Number of subjects: 23
Study 3421205 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-series analysis of food intake during menstrual cycle phases.
Number of subjects: 23
Study 5470432 — intervention group
Group type: EXPERIMENTAL
Intervention: oral oestrogen-gestogen combination
Number of subjects: 15
Study 5470432 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 15
Study 84147 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg intravaginal prostaglandin F2 alpha (P.G.F.2 alpha) in a methyl cellulose gel
Number of subjects: 80
Study 84147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 30431499 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed therapy (GDT)
Number of subjects: 64
Study 30431499 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 64
Study 29346385 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole treatment
Number of subjects: 701
Study 29346385 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel treatment
Number of subjects: 701
Study 29346385 — intervention group
Group type: EXPERIMENTAL
Intervention: Safe flooring (WASH intervention)
Number of subjects: 701
Study 29346385 — intervention group
Group type: EXPERIMENTAL
Intervention: Latrine access (WASH intervention)
Number of subjects: 701
Study 29346385 — intervention group
Group type: COMPARATOR
Intervention: WASH conditions (general)
Number of subjects: 701
Study 28000203 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous thoracic epidural block (TEA)
Number of subjects: 51
Study 28000203 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous continuous paravertebral block (PVB)
Number of subjects: 51
Study 28000203 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 51
Study 25148838 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 2003
Study 25148838 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 2003
Study 22759880 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine 60 mg/m² p.o. + Gemcitabine 1000 mg/m² i.v. on days 1 and 8 (VG)
Number of subjects: 444
Study 22759880 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine 60 mg/m² p.o. + Carboplatin AUC=5 i.v. on day 1 (VC)
Number of subjects: 444
Study 20467309 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflexology (4 weeks, 4 sessions, 30 minutes each, 5-9 days interval)
Number of subjects: 318
Study 20467309 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4 weeks, 4 sessions, 30 minutes each, 5-9 days interval)
Number of subjects: 318
Study 20467309 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 318
Study 17878473 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 17878473 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational drugs or devices
Number of subjects: 0
Study 17878473 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pathways or protocolized-care
Number of subjects: 0
Study 15732025 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitalis treatment
Number of subjects: 6797
Study 15732025 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitalis treatment with propensity analysis
Number of subjects: 6797
Study 12074253 — intervention group
Group type: EXPERIMENTAL
Intervention: Egg (640 mg additional dietary cholesterol per day)
Number of subjects: 51
Study 12074253 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 mg additional dietary cholesterol per day)
Number of subjects: 51
Study 10414766 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscoelastic heel orthosis
Number of subjects: 22
Study 7734355 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b
Number of subjects: 125
Study 7734355 — intervention group
Group type: COMPARATOR
Intervention: No maintenance therapy
Number of subjects: 125
Study 2183617 — intervention group
Group type: EXPERIMENTAL
Intervention: ampicillin 2 gm
Number of subjects: 1580
Study 2183617 — intervention group
Group type: EXPERIMENTAL
Intervention: cefazolin 2 gm
Number of subjects: 1580
Study 2183617 — intervention group
Group type: EXPERIMENTAL
Intervention: piperacillin 4 gm
Number of subjects: 1580
Study 2183617 — intervention group
Group type: EXPERIMENTAL
Intervention: cefotetan 1 gm
Number of subjects: 1580
Study 2183617 — intervention group
Group type: EXPERIMENTAL
Intervention: single-dose cephalosporin antibiotic prophylaxis
Number of subjects: 1580
Study 2183617 — intervention group
Group type: EXPERIMENTAL
Intervention: rupture of amniotic membranes for a half hour or more
Number of subjects: 1580
Study 2183617 — intervention group
Group type: EXPERIMENTAL
Intervention: internal fetal monitoring
Number of subjects: 1580
Study 7311392 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (75 mg)
Number of subjects: 7
Study 7311392 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin (300 mg/d)
Number of subjects: 7
Study 31194627 — intervention group
Group type: EXPERIMENTAL
Intervention: Video instructions (n = 23)
Number of subjects: 45
Study 31194627 — intervention group
Group type: COMPARATOR
Intervention: Handout instructions (n = 22)
Number of subjects: 45
Study 31256122 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia group
Number of subjects: 45
Study 31256122 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia group (fallers)
Number of subjects: 45
Study 31256122 — intervention group
Group type: COMPARATOR
Intervention: Cognitively-healthy controls
Number of subjects: 45
Study 27593525 — intervention group
Group type: EXPERIMENTAL
Intervention: High glycaemic index (HGI) diet
Number of subjects: 8
Study 27593525 — intervention group
Group type: COMPARATOR
Intervention: Low glycaemic index (LGI) diet
Number of subjects: 8
Study 25732936 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based app (eBalance)
Number of subjects: 99
Study 25732936 — intervention group
Group type: COMPARATOR
Intervention: Control group (introductory lecture)
Number of subjects: 99
Study 24935294 — intervention group
Group type: EXPERIMENTAL
Intervention: everolimus 1.5 mg (targeted C0 of 3‐8 ng/mL) plus reduced‐dose cyclosporine
Number of subjects: 11
Study 24935294 — intervention group
Group type: COMPARATOR
Intervention: mycophenolate mofetil 2 g/d plus standard‐dose cyclosporine
Number of subjects: 11
Study 22382155 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant tissue‐type plasminogen activator
Number of subjects: 100
Study 22382155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 19356621 — intervention group
Group type: EXPERIMENTAL
Intervention: FMP2.1/AS02A half-dose (25 microg/0.25 ml)
Number of subjects: 60
Study 19356621 — intervention group
Group type: EXPERIMENTAL
Intervention: FMP2.1/AS02A full-dose (50 microg/0.5 ml)
Number of subjects: 60
Study 19356621 — intervention group
Group type: COMPARATOR
Intervention: Control rabies vaccine
Number of subjects: 60
Study 19356621 — intervention group
Group type: EXPERIMENTAL
Intervention: FMP2.1/AS02A (both doses)
Number of subjects: 60
Study 17644511 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ(10) supplementation (300 mg/day for 1 month)
Number of subjects: 38
Study 17644511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 16167252 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive operation group (through spatium intermuscular of anal sphincter)
Number of subjects: 192
Study 12358921 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytotoxic consolidation chemotherapy following tandem transplants (TT)
Number of subjects: 75
Study 12358921 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone +/‐ interferon post TT
Number of subjects: 75
Study 10616229 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin administration
Number of subjects: 0
Study 7772356 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 300 mcg/kg orally
Number of subjects: 154
Study 7772356 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 300 mcg/kg and Metoclopramide 0.15 mg/kg orally
Number of subjects: 154
Study 7772356 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide 0.15 mg/kg orally
Number of subjects: 154
Study 7772356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 2079382 — intervention group
Group type: EXPERIMENTAL
Intervention: Troxerutine, single oral dose
Number of subjects: 0
Study 656731 — intervention group
Group type: EXPERIMENTAL
Intervention: Rewarding conditions ('good' and 'buzzer' for sociability; 'good' for impulsivity)
Number of subjects: 120
Study 656731 — intervention group
Group type: EXPERIMENTAL
Intervention: Punishing conditions ('electric shock')
Number of subjects: 120
Study 29512784 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estrogen gel and oral aspirin combination therapy
Number of subjects: 0
Study 29512784 — intervention group
Group type: COMPARATOR
Intervention: Transdermal estrogen only therapy
Number of subjects: 0
Study 27189087 — intervention group
Group type: EXPERIMENTAL
Intervention: Tian Jiu therapy (TJ)
Number of subjects: 0
Study 27189087 — intervention group
Group type: COMPARATOR
Intervention: Placebo-control group
Number of subjects: 0
Study 27189087 — intervention group
Group type: COMPARATOR
Intervention: Waitlist-control group
Number of subjects: 0
Study 24973289 — intervention group
Group type: EXPERIMENTAL
Intervention: Oximeter masking algorithm
Number of subjects: 1075
Study 24973289 — intervention group
Group type: COMPARATOR
Intervention: Higher target group (92%)
Number of subjects: 1075
Study 24973289 — intervention group
Group type: COMPARATOR
Intervention: Lower target group (88%)
Number of subjects: 1075
Study 22570264 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy
Number of subjects: 70
Study 22570264 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 70
Study 19770778 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic compliance monitoring with a reminder and monitoring device
Number of subjects: 398
Study 19770778 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 398
Study 19770778 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic compliance monitoring with a reminder and monitoring device after crossover
Number of subjects: 398
Study 19770778 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy after crossover
Number of subjects: 398
Study 19770778 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic monitoring data on compliance (study group 1)
Number of subjects: 398
Study 19770778 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (study group 2)
Number of subjects: 398
Study 17570265 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training for 8 weeks
Number of subjects: 19
Study 17570265 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control group for 8 weeks
Number of subjects: 19
Study 17570265 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 19
Study 16275007 — intervention group
Group type: COMPARATOR
Intervention: Conventional valves
Number of subjects: 807
Study 16275007 — intervention group
Group type: EXPERIMENTAL
Intervention: Silzone group
Number of subjects: 807
Study 16275007 — intervention group
Group type: EXPERIMENTAL
Intervention: Valve suture technique without pledgets
Number of subjects: 807
Study 16275007 — intervention group
Group type: COMPARATOR
Intervention: Valve suture technique with pledgets
Number of subjects: 807
Study 16275007 — intervention group
Group type: EXPERIMENTAL
Intervention: Suture technique without pledgets
Number of subjects: 807
Study 16275007 — intervention group
Group type: EXPERIMENTAL
Intervention: Silzone cuff
Number of subjects: 807
Study 11856388 — intervention group
Group type: EXPERIMENTAL
Intervention: Endosseous implant systems (IMZ, Brånemark, Transmandibular)
Number of subjects: 235
Study 11856388 — intervention group
Group type: EXPERIMENTAL
Intervention: Endosseous implant systems (IMZ, Brånemark)
Number of subjects: 235
Study 11856388 — intervention group
Group type: COMPARATOR
Intervention: Transmandibular Implant system
Number of subjects: 235
Study 10452767 — intervention group
Group type: EXPERIMENTAL
Intervention: cetirizine 0.25 mg/kg twice daily
Number of subjects: 817
Study 10452767 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 817
Study 8529776 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide oxide (2 mg initially, then 1 mg after each unformed stool, mean daily dose 2.7 mg)
Number of subjects: 0
Study 8529776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2129489 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 micrograms enprostil b.d. (part 1)
Number of subjects: 17
Study 2129489 — intervention group
Group type: COMPARATOR
Intervention: Placebo (part 1)
Number of subjects: 17
Study 2129489 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 micrograms enprostil b.d. (part 2)
Number of subjects: 17
Study 2129489 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 micrograms enprostil b.d. (part 2)
Number of subjects: 17
Study 382433 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin 5,000 IU subcutaneously twice daily
Number of subjects: 21
Study 382433 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 21
Study 31604623 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-way stopcock (TWS) connectors
Number of subjects: 180
Study 31604623 — intervention group
Group type: COMPARATOR
Intervention: Needleless connectors (NC)
Number of subjects: 180
Study 31604623 — intervention group
Group type: COMPARATOR
Intervention: Other types of connectors or catheters
Number of subjects: 180
Study 31335572 — intervention group
Group type: EXPERIMENTAL
Intervention: NBP607-QIV
Number of subjects: 454
Study 31335572 — intervention group
Group type: COMPARATOR
Intervention: Control (inactivated trivalent influenza vaccine)
Number of subjects: 454
Study 31335572 — intervention group
Group type: EXPERIMENTAL
Intervention: NBP607-QIV and Control
Number of subjects: 454
Study 31335572 — intervention group
Group type: EXPERIMENTAL
Intervention: Solicited AEs for both groups
Number of subjects: 454
Study 27801753 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher enteral protein intake (1 g/100 mL expressed breast milk)
Number of subjects: 120
Study 27801753 — intervention group
Group type: COMPARATOR
Intervention: Lower enteral protein intake (0.4 g/100 mL expressed breast milk)
Number of subjects: 120
Study 26192873 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-initiation group
Number of subjects: 4685
Study 26192873 — intervention group
Group type: COMPARATOR
Intervention: Deferred-initiation group
Number of subjects: 4685
Study 26192873 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 4685
Study 23792541 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (100 μg)
Number of subjects: 21
Study 23792541 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 21726586 — intervention group
Group type: EXPERIMENTAL
Intervention: TM-Sidhi practice
Number of subjects: 2
Study 21726586 — intervention group
Group type: COMPARATOR
Intervention: TM practice
Number of subjects: 2
Study 18923805 — intervention group
Group type: EXPERIMENTAL
Intervention: Gynemesh PS
Number of subjects: 190
Study 18923805 — intervention group
Group type: COMPARATOR
Intervention: Pelvicol
Number of subjects: 190
Study 16407905 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino-acid drink containing l-tryptophan (T+)
Number of subjects: 0
Study 16407905 — intervention group
Group type: COMPARATOR
Intervention: Amino-acid drink without l-tryptophan (T-)
Number of subjects: 0
Study 12937048 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm infants
Number of subjects: 39
Study 16422035 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard oral hygiene regimen
Number of subjects: 63
Study 16422035 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical analysis techniques (Standard Normal Deviate, elimination of outliers)
Number of subjects: 63
Study 16422035 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial screening and professional prophylaxis
Number of subjects: 63
Study 16422035 — intervention group
Group type: COMPARATOR
Intervention: Random assignment to test and control groups
Number of subjects: 63
Study 9510924 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood transfusion using cell salvage
Number of subjects: 100
Study 9510924 — intervention group
Group type: COMPARATOR
Intervention: Allogeneic blood transfusion
Number of subjects: 100
Study 8090337 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (400 micrograms/day for 12 months)
Number of subjects: 60
Study 8090337 — intervention group
Group type: COMPARATOR
Intervention: Control (aluminium and magnesium hydroxide)
Number of subjects: 60
Study 8090337 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol + group
Number of subjects: 60
Study 8090337 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol-group
Number of subjects: 60
Study 3045281 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (approximately 0.4 mg/kg)
Number of subjects: 193
Study 3045281 — intervention group
Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 193
Study 30383458 — intervention group
Group type: EXPERIMENTAL
Intervention: Game group (serious game 'Hit the Cancer', 30 minutes/day, 5 days/week for 3 weeks)
Number of subjects: 35
Study 30383458 — intervention group
Group type: COMPARATOR
Intervention: Nongame group (usual care)
Number of subjects: 35
Study 30383458 — intervention group
Group type: EXPERIMENTAL
Intervention: Game group
Number of subjects: 35
Study 30383458 — intervention group
Group type: COMPARATOR
Intervention: Nongame group
Number of subjects: 35
Study 25588153 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Adherence and Depression (CBT-AD)
Number of subjects: 89
Study 25588153 — intervention group
Group type: COMPARATOR
Intervention: Enhanced treatment as usual
Number of subjects: 89
Study 23937067 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant starch and Lactobacillus acidophilus yoghurt (LC1)
Number of subjects: 19
Study 21340377 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory muscle training (RMT)
Number of subjects: 38
Study 21340377 — intervention group
Group type: COMPARATOR
Intervention: Control group (CO)
Number of subjects: 38
Study 18181252 — intervention group
Group type: EXPERIMENTAL
Intervention: ABIO-08/01 (40 mg)
Number of subjects: 16
Study 18181252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 15879169 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat extraction device (local subatmospheric pressure 35‐45 mmHg and heat sink 18‐22 degrees C)
Number of subjects: 8
Study 15879169 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat extraction device
Number of subjects: 8
Study 15879169 — intervention group
Group type: COMPARATOR
Intervention: Control (no device)
Number of subjects: 8
Study 15879169 — intervention group
Group type: COMPARATOR
Intervention: Cooling only (hand cooling)
Number of subjects: 8
Study 15879169 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling and subatmospheric pressure
Number of subjects: 8
Study 12935434 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicilina 500 mg capsules
Number of subjects: 24
Study 12935434 — intervention group
Group type: COMPARATOR
Intervention: Amoxil 500 mg capsules
Number of subjects: 24
Study 11092517 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile intravenous insulin therapy (PIVIT) in addition to intensive therapy (IT)
Number of subjects: 49
Study 11092517 — intervention group
Group type: COMPARATOR
Intervention: Intensive therapy (IT)
Number of subjects: 49
Study 9414440 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric oxide (NO)
Number of subjects: 0
Study 9414440 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 1957968 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine (FLN) administered as drops in a single evening dose of 5 mg (patients <10 years) or 10 mg (patients >10 years)
Number of subjects: 20
Study 1957968 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6274476 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective venous catheterisation and sampling for ACTH
Number of subjects: 23
Study 31649275 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey on perception of wildfire smoke hazards
Number of subjects: 2237
Study 28847532 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted energy availability (RES; 15kcal·kgLBM‐1·d‐1)
Number of subjects: 22